Firefly Neuroscience financials
$1.62−4.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $1.1M | $108.0K |
| Gross profit | $645.0K | $108.0K |
| Gross margin | 56.5% | 100.0% |
| Operating income | -$8.9M | -$10.1M |
| Net income | -$24.5M | -$10.5M |
| Net margin | −2148.1% | −9685.2% |
| Diluted EPS | $-1.97 | $-1.60 |
| EBITDA | -$8.4M | -$9.1M |
| Operating cash flow | -$8.2M | -$6.2M |
| Free cash flow | -$8.3M | -$6.3M |
| Diluted shares | 12.4M | 6.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $2.7M | $1.8M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $694.0K |
| Total assets | $10.5M | $4.6M |
| Total liabilities | $2.8M | $5.0M |
| Shareholders' equity | $7.6M | -$375.0K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology